Dose‐adjusted EPOCH and rituximab ( DA‐EPOCH‐R ) in older patients with high‐risk aggressive diffuse large B‐cell lymphoma: A real‐life multicenter study by the Croatian Cooperative Group for Hematologic diseases ( KroHem )
European Journal of Haematology · 2023
DOI: 10.1111/ejh.13957 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Zdravko Mitrovic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, University Hospital Dubrava, Zagreb, Croatia. Hauptthemen laut MEDLINE: Hematologic Diseases, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Purpose
Dose‐adjusted EPOCH and rituximab (DA‐EPOCH‐R) is a regimen used for the treatment of high‐risk diffuse large B‐cell lymphoma (DLBCL) designed to overcome resistance to standard R‐CHOP by combining prolonged exposure of lymphoma cells to cytotoxic agents and dose‐adjustment based on toxicity. Data on outcomes of older patients are scarce. Patients and Methods We collected data on patients with newly diagnosed high‐risk DLBCL older than 60 years treated with DA‐EPOCH‐R. High‐risk patients were defined by the age‐adjusted international prognostic index score 2 or 3.
Results
A total of 120 patients were included. Median age was 69 years (range 60–82). Response rate was 74%; with 59% complete responses. Dose of DA‐EPOCH‐R was escalated in 50 patients (42%). Three‐year progression‐free survival (PFS) and overall survival (OS) was 53% and 58%, respectively, with treatment‐related mortality (TRM) of 13%. In univariate analysis, favorable prognostic factors were performance status (PS) (0–2 vs. 3–4), age (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, University Hospital Dubrava, Zagreb, Croatia.
- Medical School University of Zagreb, Zagreb, Croatia.
- Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia.
- Division of Hematology, Department of Internal Medicine, University Hospital Center Sisters of Mercy and School of Dental Medicine, University of Zagreb, Zagreb, Croatia.
- Division of Hematology, Department of Internal Medicine, University Hospital Center Osijek and Medical School University of Osijek, Osijek, Croatia.
- Division of Hematology, Department of Internal Medicine, University Hospital Center Split and Medical School University of Split, Split, Croatia.
ORCID-Profile: Zdravko Mitrovic, Dino Dujmovic, Ozren Jaksic, Sandra Basic Kinda, Petar Gacina, Vlatka Perisa, Davor Galusic, Hrvoje Holik, Vlatko Pejsa, Igor Aurer
Zitieren
APA
Mitrovic, Z., Dujmovic, D., Jaksic, O., Kinda, S. B., Gacina, P., Perisa, V., Prka, Z., Dreta, B., Galusic, D., Holik, H., Pejsa, V., & Aurer, I. (2023). Dose‐adjusted EPOCH and rituximab ( DA‐EPOCH‐R ) in older patients with high‐risk aggressive diffuse large B‐cell lymphoma: A real‐life multicenter study by the Croatian Cooperative Group for Hematologic diseases ( KroHem ). European Journal of Haematology. https://doi.org/10.1111/ejh.13957
Vancouver
Mitrovic Z, Dujmovic D, Jaksic O, Kinda SB, Gacina P, Perisa V, et al. Dose‐adjusted EPOCH and rituximab ( DA‐EPOCH‐R ) in older patients with high‐risk aggressive diffuse large B‐cell lymphoma: A real‐life multicenter study by the Croatian Cooperative Group for Hematologic diseases ( KroHem ). European Journal of Haematology. 2023. doi:10.1111/ejh.13957
BibTeX
@article{Mitrovic2023,
author = {Mitrovic, Zdravko and Dujmovic, Dino and Jaksic, Ozren and Kinda, Sandra Basic and Gacina, Petar and Perisa, Vlatka and Prka, Zeljko and Dreta, Barbara and Galusic, Davor and Holik, Hrvoje and Pejsa, Vlatko and Aurer, Igor},
title = {Dose‐adjusted EPOCH and rituximab ( DA‐EPOCH‐R ) in older patients with high‐risk aggressive diffuse large B‐cell lymphoma: A real‐life multicenter study by the Croatian Cooperative Group for Hematologic diseases ( KroHem )},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.13957}
}
EUVIMED